Colorado Board Proposes Enbrel’s Medicare Price for Payment Cap

Colorado is proposing to cap health plan payments for the blockbuster biologic Enbrel at Medicare’s maximum negotiated price as the state continues to face litigation seeking to prevent the limit from taking effect.

The Colorado Prescription Drug Affordability Board voted Friday to seek public comment on a proposal to set a health plan payment cap at $583.59 per unit, or the current maximum fair price for Amgen Inc.‘s autoimmune treatment that’s set to go into effect in the Medicare program in January 2026.

The Colorado proposal, if finalized, would apply to all health plans in Colorado and would make ...